Volume Spike Investor

Vical Incorporated (NASDAQ: VICL) is trading up this morning on its news that TransVax CMV vaccine elicited a long-term immune response in Phase II trial to demonstrate an overall increase in cellular immune responses compared with placebo at the 7-month immunogenicity data point.  This is important in protecting recovering transplant recipients against CMV disease.  The four-month interim analysis was sustained through the seven-month data point.  The company will review the final trial data in the first half of 2010.  Shares were up as much 6% but at 8:25 AM EST we have 13,000 shares traded versus average volume of 1.3 million shares.  At this time the stock is up 5% at $4.16. Jon Ogg